CERC-301

DRUG2 trials

Sponsors

Avalo Therapeutics, Inc.

Conditions

Major Depressive Disorder

Phase 2

A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

CompletedNCT01941043

Avalo Therapeutics, Inc.Major Depressive Disorder

Start: 2013-11-30End: 2014-10-31Updated: 2017-12-21

A Study of Intermittent Doses of CERC-301 in MDD

CompletedNCT02459236

Avalo Therapeutics, Inc.Major Depressive Disorder

Start: 2015-06-30End: 2016-12-31Updated: 2017-09-28